Eutilex Co., Ltd.

National Cancer Center

Bio-support Co., Ltd.

Byoung S Kwon

Young Ho Kim

Ho-Sik Oh

Seoung-Joo Lee

Joong Won Lee

Kwang-Hui Kim

Hyun Tae Son

Sun Woo Im

Don-Gil Lee

Beom-Kyu Choi

Young-Ho Kim

Seung Hyun Lee

Jin Kyung Choi

Seung-Joo Lee

Kwang Hee Kim

Insoo Park

Hyeok-Jun Park

Chungyong Han

Seung-hoon Lee

Hye Jeong Kim

Jin-Soo Lee

Jin Sung Park

Young-Joo Lee

Hanna Lee

Young-Woo Kim

Sang-Jae Park

Heon Yoo

Eun Hye Yoo

Sang-Yoon Park

Joongwon Lee

Ho-sik Oh

Ji Won Chung

Jung Yun Lee

Young Gyoon Chang

Seunghyun Lee

Yeonji Oh

Bo Rim Yi

Hyun-Guy Kang

Byung-Kiu Park

Hyeon-Seok Eom

Sunhee Hwang

Seung Hee Han

Sung Min Park

Eunhye Yoo

Mun Ki Kim

You Hyun Kang

The present invention provides a bispecific epitope binding protein comprising an anti-4-1BB agonist antibody and a PD-1 protein or a fragment thereof that binds to PD-L1 with high affinity. The bispecific epitope binding protein simultaneously and independently binds to 4-1BB and PD-L1, which engage 4-1BB upregulated T cells, especially effector CD8+ T cells, with tumor cells expressing PD-L1. These interactions induce strong activation of the cytotoxic activity of anti-tumor effector CD8+ T cells by both blocking PD-1/PD-L1-mediated inhibitory signaling and activating 4-1BB-mediated costimulatory signaling in mouse models. This bispecific epitope binding protein has a much stronger oncolytic effect compared to each component alone.

Bispecific epitope binding protein comprising anti-4-1BB antibody and a PD-1 protein or fragments thereof and use thereof

A bispecific epitope binding protein having a multimer of four single-chain chimeric polypeptides of two single-chain chimeric heavy chains and two single-chain chimeric light chains. The bispecific epitope binding protein has a first antigen binding domain that binds specifically to HER2 and a second antigen binding domain that binds specifically to 4-1BB.

Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof

The present invention relates to an antigen-binding molecule comprising a heavy chain variable region comprising a heavy-chain complementarity-determining region 1 (HCDR1) comprising an amino acid sequence represented by Sequence No. 1, an HCDR2 comprising an amino acid sequence represented by Sequence No. 2, and an HCDR3 comprising an amino acid sequence represented by Sequence No. 3; a light-chain variable region comprising a light-chain complementarity-determining region 1 (LCDR1) comprising an amino acid sequence represented by Sequence No. 4, an LCDR2 comprising an amino acid sequence represented by Sequence No. 5, and an LCDR3 comprising an amino acid sequence represented by Sequence No. 6; wherein the antigen-binding molecule is a T cell receptor (TCR); and to a cell line expressing the same.

Chimeric antigen receptor that binds HLA-DR and CAR-T cell

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims.

Anti-human VSIG4 antibodies and uses thereof

Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFNγ, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.

Anti-human 4-1BB antibodies and uses thereof

The present invention relates to a pharmaceutical composition for preventing or treating cancer comprising cancer antigen-specific cytotoxic T cells; the pharmaceutical composition comprises about 7&#xd7;10cells/mL or more, and of the about 7&#xd7;10cells/mL, about 90% or more are CD8+ T cells.

Cancer antigen specific cytotoxic T cell

Provided is a monoclonal antibody which specifically recognizes B cell lymphoma cells and a use thereof. More specifically, provided are the monoclonal antibody; a pharmaceutical composition for preventing or treating B cell lymphoma including the monoclonal antibody; a composition for diagnosing B cell lymphoma including the monoclonal antibody; a method for providing information for diagnosing B cell lymphoma using the monoclonal antibody; a chimeric antigen receptor (CAR) protein including i) the antibody, ii) a transmembrane domain, and iii) an intracellular signaling domain; a recombinant vector which expresses the CAR protein; a CAR-modified T cell transformed with the recombinant vector; a pharmaceutical composition for preventing or treating B cell lymphoma including the CAR-modified T cell; and an antibody-drug conjugate wherein the monoclonal antibody and a drug are conjugated.

Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof

The present invention relates to a novel epitope that converts T cell to type 1 helper T (T1) cell. Specifically, the present invention relates to an epitope constituting the 56to 65amino acids (SEQ ID No. 2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to T1 cell and a method for converting T cell to T1 cell, a pharmaceutical composition comprising the antibody for preventing or treating cancer, a method for treating cancer using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody.

Epitope for switching to T1 cell and use thereof

The present invention relates to a novel epitope to convert T cell to type 2 helper T (T2) cell. Specifically, the present invention relates to an epitope constituting the 20to 30amino acids (SEQ ID No.2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to T2 cell and a method of conversion, a pharmaceutical composition comprising the antibody for preventing or treating autoimmune disease, and a method for treating autoimmune disease using the antibody.

Epitope for switching to T2 cell and use thereof

Provided are antibodies and antigen-binding fragment thereof that bind to VSIG4. Various in vitro and in vivo methods and compositions related to antibodies. Methods include prevention and/or therapeutic treatment of cancer using an antibody or an antigen-binding fragment that binds to VSIG4.

Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not found in a reference anti-human 4-1BB antibody, where said features may improve certain characteristics of the antibody relative to a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFN&#x3b3;, as well as detection, prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof.

Provided are IFN-&#x3b3;-Inducible Regulatory T Cell Convertible Anti-Cancer (IRTCA) antibodies and antigen-binding fragment thereof that bind to an activation-inducible TNFR (AITR) polypeptide. Various in vitro and in vivo methods and compositions related to IRTCA antibodies described herein are also provided. Methods include, for example, changing cytokine secretion from T cells in vivo or in vitro and prevention and/or therapeutic treatment of cancer using an IRTCA antibody or fragment thereof.

IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof

The present invention relates to a novel epitope to convert T cell to type 17 helper T (T17) cell. Specifically, the present invention relates to an epitope constituting the 41st to 50th amino acids (SEQ ID No.2) of extracellular domain (ECD) of activation-inducible tumor necrosis factor receptor (AITR), an antibody recognizing the epitope, a polynucleotide encoding the epitope, a polynucleotide encoding the antibody, an expression vector comprising the polynucleotide encoding the epitope or antibody, a transformant introduced with the vector, a composition comprising the antibody for converting T cell to T17 cell and a method of conversion for the same, a pharmaceutical composition comprising the antibody for preventing or treating infectious disease, a method for treating infectious disease using the antibody, a composition comprising the antibody for enhancing immunity, and a method for enhancing immunity using the antibody.

Epitope for switching to T17 cell and use thereof

Provided is a method for isolating and proliferating autologous cancer antigen-specific CD8T cells, and more particularly, a method for selecting an epitope recognized by CD8T cells from autologous cancer antigens present in blood of individual cancer patients; and isolating autologous cancer antigen-specific CD8T cells by using a peptide of the selected epitope, and a method of massively proliferating CD8T cells by using the method. According to the present invention, it is possible to isolate autologous cancer antigen-specific CD8T cells by using the peptide of the CD8 T cell epitope of the autologous cancer antigen present in blood of individual cancer patients instead of a heterologous antigen. Therefore, by using T cells recognizing the autologous cancer antigen, it is possible to effectively select and eliminate cancer cells derived from the cancer patient's own cells. Thus, T cells can be applied to treatment and alleviation of cancer diseases without side effects.

Methods for isolating and proliferating autologous cancer antigen-specific CD8T cells

Growing community of inventors

Gwangmyeong-si, South Korea

Byoung S Kwon